Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study

REXULTI Clinical Summary – Fleischacker et al
1-4

AU-REXU-0204. February 2020

  • Body

    PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia. This product is not listed on the PBS for the treatment of agitation associated with Alzheimer’s dementia.

  • Body

    Please review Approved Product Information before prescribing. 
    Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:

    REXULTI PI

    REXULTI® is a registered trademark of H. Lundbeck A/S. REXULTI® is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.